Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799946 | 0.93 | SLC6A3 (0.54) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17800046 | 0.92 | SLC6A3 (0.54) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17799809 | 0.89 | SLC6A3 (0.59) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17799921 | 0.89 | SLC6A3 (0.46) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17799801 | 0.88 | SLC6A3 (0.51) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17799853 | 0.88 | SLC6A3 (0.45) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17799839 | 0.88 | SLC6A3 (0.59) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17799822 | 0.87 | SLC6A3 (0.49) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17799895 | 0.87 | SLC6A3 (0.45) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E | |
| SCHEMBL17800018 | 0.87 | SLC6A3 (0.49) | SLC6A3CYP1A2CYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | claimed |
| EP-3226867-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | Ananthan, Subramaniam (US) | 2017-10-11 | — | — | EP | claimed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | claimed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | claimed |
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3226867-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | Ananthan, Subramaniam (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090296-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | ANANTHAN SUBRAMANIAM (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A3 3/4885CYP1A2 796/4885CYP3A4 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.